LivaNova (LIVN) Projected to Post Quarterly Earnings on Wednesday

Key Points

• LivaNova (LIVN) is set to release its Q2 2025 earnings report on August 6th, with analysts forecasting earnings of $0.84 per share and revenue of $332.20 million.
• The stock has seen positive movement recently, opening at $43.99 and experiencing a 1.2% increase.
• Rating agencies have shown varying outlooks, with an average target price of $59.29, indicating a general sentiment of "buy" among analysts.

LivaNova (NASDAQ:LIVN - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of $0.84 per share and revenue of $332.20 million for the quarter.

LivaNova Stock Up 1.2%

LIVN stock opened at $43.99 on Wednesday. The company has a quick ratio of 1.37, a current ratio of 1.58 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $2.40 billion, a PE ratio of -10.76 and a beta of 0.90. LivaNova has a twelve month low of $32.48 and a twelve month high of $57.35. The stock has a 50-day simple moving average of $44.66 and a two-hundred day simple moving average of $42.97.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Strs Ohio bought a new position in LivaNova during the first quarter valued at approximately $130,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in LivaNova by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company's stock valued at $1,394,000 after acquiring an additional 1,360 shares during the last quarter. Intech Investment Management LLC grew its position in LivaNova by 19.6% during the first quarter. Intech Investment Management LLC now owns 43,879 shares of the company's stock valued at $1,724,000 after acquiring an additional 7,195 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in LivaNova by 10.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company's stock valued at $6,633,000 after acquiring an additional 15,405 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in LivaNova by 4.6% in the first quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company's stock valued at $32,012,000 after purchasing an additional 36,094 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Robert W. Baird boosted their price objective on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Needham & Company LLC reissued a "buy" rating and set a $64.00 price objective on shares of LivaNova in a report on Tuesday, May 13th. Barclays cut their price objective on LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a report on Thursday, May 8th. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a report on Tuesday, May 20th. Finally, Wall Street Zen lowered LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $59.29.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.